{
  "source": "PA-Med-Nec-Aqneursa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2355-3\nProgram Prior Authorization/Medical Necessity\nMedication Aqneursa™ (levacetylleucine)\nP&T Approval Date 11/2024, 1/2025, 3/2025\nEffective Date 6/1/2025\n1. Background\nAqneursa (glycerol phenylbutyrate) is indicated for the treatment of neurological manifestations\nof Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Aqneursa will be approved based on all of the following criteria:\na. Both of the following:\n(1) Diagnosis of Niemann-Pick disease type C (NPC)\n-AND-\n(2) Diagnosis has been genetically confirmed by mutation analysis of NPC1 and NPC2\ngenes\n-AND-\nb. Aqneursa is being used to treat neurological manifestations of NPC\n-AND-\nc. One of the following:\n(1) Aqneursa is prescribed in combination with miglustat\n-OR-\n(2) History of failure, contraindication, or intolerance to miglustat\n-AND-\nd. Patient is not receiving Aqneursa in combination with Miplyffa (arimoclomol)\n-AND-\ne. Aqneursa is prescribed by or in consultation with a provider with expertise in the\n© 2025 UnitedHealthcare Services Inc.\n1\ntreatment of NPC\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Aqneursa will be approved based on all of the following criteria:\na. Documentation of positive clinical response to Aqneursa therapy (e.g., slowed disease\nprogression from baseline based on assessment with NPC–specific scales)\n-AND-\nb. One of the following:\n(1) Aqneursa is prescribed in combination with miglustat\n-OR-\n(2) History of failure, contraindication, or intolerance to miglustat\n-AND-\nc. Patient is not receiving Aqneursa in combination with Miplyffa (arimoclomol)\n-AND-\nd. Aqneursa is prescribed by or in consultation with a provider with expertise in the\ntreatment of NPC\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage ",
    "ovider with expertise in the\ntreatment of NPC\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Aqneursa [package insert]. Austin TX: IntraBio Inc.; September 2024.\n2. Geberhiwot T, Moro A, Dardis A, et al. Consensus clinical management guidelines for Niemann-\nPick disease type C. Orphanet J Rare Dis. 2018;13(1):50. Published 2018 Apr 6.\ndoi:10.1186/s13023-018-0785-7\n© 2025 UnitedHealthcare Services Inc.\n2\nProgram Prior Authorization/Medical Necessity - Aqneursa (levacetylleucine)\nChange Control\n11/2024 New program.\n1/2025 Added criteria that Aqneursa not taken in combination with Miplyffa.\n3/2025 Added criteria that Aqneursa taken in combination with miglustat or history\nof failure, contraindication, or intolerance to miglustat.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}